| Aztreonam |
NS, D5W |
3–5 min (IV push) or 30 min IV |
1–2 g q6–8h |
75–125 mL/hr |
For penicillin-allergic patients; monobactam class |
| Cefazolin |
NS, D5W |
3 min (IV push) or 30 min IV |
1–2 g q8h |
75–125 mL/hr |
Common for surgical prophylaxis |
| Cefepime |
NS, D5W |
30 min IV infusion |
1–2 g q8–12h |
75–125 mL/hr |
Broad-spectrum; neurotoxicity risk in renal failure |
| Ceftriaxone |
NS, D5W |
30 min IV infusion |
1–2 g q24h |
75–125 mL/hr |
Avoid calcium-containing fluids (risk of precipitation) |
| Cefotaxime |
NS, D5W |
30 min IV infusion |
1–2 g q6–8h |
75–125 mL/hr |
Good CNS penetration; alternative to ceftriaxone |
| Cefuroxime |
NS, D5W |
3 min (IV push) or 15–30 min |
750 mg–1.5 g q8h |
75–125 mL/hr |
Second-gen cephalosporin |
| Clindamycin |
NS, D5W |
30–60 min IV infusion |
600–900 mg q8h |
75–125 mL/hr |
Avoid rapid infusion (risk of arrhythmia and hypotension) |
| Daptomycin |
NS |
2 min (IV push) or 30 min IV |
4–6 mg/kg q24h |
75–125 mL/hr |
Inactivated by lung surfactant – not for pneumonia |
| Ertapenem |
NS |
30 min IV infusion |
1 g q24h |
75–125 mL/hr |
Not active against Pseudomonas |
| Gentamicin |
NS, D5W |
30–60 min IV infusion |
5–7 mg/kg q24h (extended interval) |
75–125 mL/hr |
Requires therapeutic drug monitoring (TDM) |
| Meropenem |
NS, D5W |
30 min IV or extended 3 h |
1–2 g q8h |
75–125 mL/hr |
Time-dependent; extended infusion may improve efficacy |
| Piperacillin/Tazobactam |
NS |
30 min IV infusion or extended 4 h |
3.375–4.5 g q6–8h |
75–125 mL/hr |
Prolonged infusion more effective in severe infections |
| Tobramycin |
NS, D5W |
30–60 min IV infusion |
5–7 mg/kg q24h |
75–125 mL/hr |
Ototoxicity and nephrotoxicity risk; TDM required |
| Vancomycin |
NS, D5W |
1–2 hours (slow infusion) |
15–20 mg/kg q8–12h |
75–125 mL/hr |
Infuse slowly to prevent “red man syndrome”; monitor troughs |
